Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977507 · ClinicalTrials.gov registry record · NA
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
A NA study of Melasma, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02977507 is a NA study of Melasma that has completed, run by Allergan. The registered enrollment target is 18 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02977507, a NA study of Melasma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
Conditions Studied
Interventions
- OTHER Lytera 2.0
- DRUG 4% Hydroquinone Topical Cream
- OTHER SkinMedica Facial Cleanser
- OTHER SkinMedica Rejuvenative Moisturizer
- OTHER SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Study Locations (1)
New York
- Mount Sinai St. Luke's Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2017-10-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02977507
The ClinicalTrials.gov registry entry for NCT02977507 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (58% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 5 interventions - of which Lytera 2.0 is the first listed.
NCT02977507 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02977507 about?
NCT02977507 is a clinical study titled "Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma". The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
What is the current status of trial NCT02977507?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-12-13. Estimated completion is 2017-10-09.
What conditions does trial NCT02977507 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT02977507?
The interventions under investigation include: Lytera 2.0 (OTHER), 4% Hydroquinone Topical Cream (DRUG), SkinMedica Facial Cleanser (OTHER), SkinMedica Rejuvenative Moisturizer (OTHER), SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen (OTHER).
Who is sponsoring clinical trial NCT02977507?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977507 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.